{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:33:04Z","timestamp":1790008384999,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ijpharm.2017.04.013","type":"journal-article","created":{"date-parts":[[2017,4,8]],"date-time":"2017-04-08T13:03:48Z","timestamp":1491656628000},"page":"139-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting"],"prefix":"10.1016","volume":"525","author":[{"given":"Raquel","family":"Fern\u00e1ndez-Garc\u00eda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"de Pablo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Paloma","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores R.","family":"Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpharm.2017.04.013_bib0005","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/bm0257614","article-title":"Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity","volume":"4","author":"Adams","year":"2003","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0010","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/mmy\/myv111","article-title":"Comparison between liposomal formulations of amphotericin B","volume":"54","author":"Adler-Moore","year":"2016","journal-title":"Med. Mycol."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejpb.2016.08.016","article-title":"An investigation into the use of polymer blends to improve the printability of and regulate drug release from pharmaceutical solid dispersions prepared via fused deposition modeling (FDM) 3D printing","volume":"108","author":"Alhijjaj","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0020","first-page":"603","article-title":"Antifungal agents for the treatment of systemic fungal infections in children. Canadian Paediatric Society","volume":"15","author":"Allen","year":"2010","journal-title":"Infect. Dis. Immun. Committee"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0025","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1093\/jac\/dkn539","article-title":"Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis","volume":"63","author":"Amaral","year":"2009","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0030","series-title":"Amphotericin B Lipid Complex Versus Amphotericin B for Treatment of Invasive Candidiasis: A Prospective, Randomized, Multicenter Trial","author":"Anaissie","year":"1995"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0035","doi-asserted-by":"crossref","first-page":"580","DOI":"10.3109\/02652040902797516","article-title":"Amphotericin B microspheres: a therapeutic approach to minimize toxicity while maintaining antifungal efficacy","volume":"26","author":"Angra","year":"2009","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0040","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1128\/AAC.01984-12","article-title":"Immunoadjuvant chemotherapy of visceral leishmaniasis in hamsters using amphotericin B-encapsulated nanoemulsion template-based chitosan nanocapsules","volume":"57","author":"Asthana","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0045","first-page":"275","article-title":"Liposomal formulations of amphotericin B: differences according to the scientific evidence","volume":"28","author":"Azanza","year":"2015","journal-title":"Revista espanola de quimioterapia: publicacion oficial de la Sociedad Espanola de Quimioterapia"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.mycmed.2012.10.003","article-title":"New strategy for enhancing the therapeutic index of fungizone","volume":"23","author":"Belkherroubi-Sari","year":"2013","journal-title":"J. Mycol. Med."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0055","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1086\/341401","article-title":"A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients","volume":"35","author":"Bowden","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0060","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jps.10065","article-title":"Amphotericin B in oil-water lecithin-based microemulsions: formulation and toxicity evaluation","volume":"91","author":"Brime","year":"2002","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0065","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1093\/jac\/dkg266","article-title":"Comparative pharmacokinetics and safety of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and amphotericin B deoxycholate in animal models","volume":"52","author":"Brime","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/j.1365-2125.1983.tb02152.x","article-title":"Absorption of orally administered amphotericin B lozenges","volume":"16","author":"Ching","year":"1983","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0075","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1208\/s12249-007-9022-8","article-title":"Formulation and evaluation of microemulsion based delivery system for amphotericin B","volume":"9","author":"Darole","year":"2008","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0080","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/504492","article-title":"Pharmacology of systemic antifungal agents","volume":"43","author":"Dodds","year":"2006","journal-title":"Clin. Infect. Dis."},{"issue":"Suppl. 1","key":"10.1016\/j.ijpharm.2017.04.013_bib0085","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.suppl_1.31","article-title":"Overview of the lipid formulations of amphotericin B","volume":"49","author":"Dupont","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jac\/dkg351","article-title":"Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice","volume":"52","author":"Espuelas","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0095","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3109\/10428190109097650","article-title":"Comparison of amphotericin B lipid complex (ABLC) vs. ambisome in the treatment of suspected or documented fungal infections in patients with leukemia","volume":"40","author":"Fleming","year":"2001","journal-title":"Leukem. Lymphoma"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0100","series-title":"Farmacolog\u00eda Humana","author":"Florez","year":"1998"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0105","first-page":"351","article-title":"Preparation and antifungal activity of spray-dried amphotericin B-loaded nanospheres","volume":"19","author":"Gharib","year":"2011","journal-title":"Daru"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0110","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1128\/AAC.43.3.702","article-title":"Amphotericin B- and fluconazole-resistant Candida spp. Aspergillus fumigatus, and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides","volume":"43","author":"Helmerhorst","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0115","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.biomaterials.2009.11.016","article-title":"Injectable in situ cross-linking hydrogels for local antifungal therapy","volume":"31","author":"Hudson","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.7326\/0003-4819-137-2-200207160-00008","article-title":"Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS","volume":"137","author":"Johnson","year":"2002","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0125","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1097\/00002030-199712000-00010","article-title":"Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS associated cryptococcal memingitis","volume":"11","author":"Leenders","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0130","series-title":"Vel\u00e1zquez. Farmacolog\u00eda B\u00e1sica Cl\u00ednica","author":"Lorenzo","year":"2008"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0135","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/hiv.12350","article-title":"Biological markers of fertility (inhibin-B) in HIV-infected men: influence of HIV infection and antiretroviral therapy","volume":"17","author":"Moreno-Perez","year":"2016","journal-title":"HIV Med."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0140","first-page":"7","article-title":"Aspectos epidemiol\u00f3gicos de las micosis en el paciente cr\u00edtico","volume":"21","author":"Peman","year":"2008","journal-title":"Revista Espa\u00f1ola de Quimioterapia"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0145","first-page":"198","article-title":"Amphotericin B cochleates: a vehicle for oral delivery","volume":"5","author":"Perlin","year":"2004","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0150","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.drup.2007.04.002","article-title":"Resistance to echinocandin-class antifungal drugs","volume":"10","author":"Perlin","year":"2007","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0155","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1046\/j.1365-2141.1997.2473063.x","article-title":"A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients","volume":"98","author":"Prentice","year":"1997","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0160","series-title":"Merck Manual","article-title":"Antifungal drugs","author":"Revankar","year":"2017"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0165","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1080\/03639040601077349","article-title":"Assessing the antifungal activity of a new oral lipid-based amphotericin B formulation following administration to rats infected with Aspergillus fumigatus","volume":"33","author":"Risovic","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0170","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a019703","article-title":"Antifungal drug development: challenges, unmet clinical needs, and new approaches","volume":"4","author":"Roemer","year":"2014","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0175","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ijpharm.2014.07.004","article-title":"New amphotericin B-gamma cyclodextrin formulation for topical use with synergistic activity against diverse fungal species and Leishmania spp","volume":"473","author":"Ruiz","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0180","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.eimc.2009.04.001","article-title":"Antif\u00fangicos para uso sist\u00e9mico","volume":"27","author":"Ruiz-Camps","year":"2009","journal-title":"Enfermedades infecciosas y microbiolog\u00eda cl\u00ednica"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0185","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/myc.12330","article-title":"Antifungal drug resistance among Candida species: mechanism and clinical impact","volume":"58","author":"Sanguinetti","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0190","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijpharm.2012.07.065","article-title":"A novel formulation of solubilised amphotericin B designed for ophthalmic use","volume":"437","author":"Serrano","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0195","first-page":"250","article-title":"Amphotericin B formulations \u2013 the possibility of generic competition","volume":"1","author":"Serrano","year":"2013","journal-title":"Pharm. Technol."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0200","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ijpharm.2013.02.038","article-title":"Hemolytic and pharmacokinetic studies of liposomal and particulate amphotericin B formulations","volume":"447","author":"Serrano","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0205","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/mp500527x","article-title":"Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles","volume":"12","author":"Serrano","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.jconrel.2010.06.018","article-title":"Angiopep-2 modified PE-PEG based polymeric micelles for amphotericin B delivery targeted to the brain","volume":"147","author":"Shao","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0215","doi-asserted-by":"crossref","first-page":"6898","DOI":"10.1016\/j.biomaterials.2012.06.050","article-title":"A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection","volume":"33","author":"Shao","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0220","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1097\/QAD.0000000000000992","article-title":"HIV infection and arterial stiffness among older-adults taking antiretroviral therapy in rural Uganda","volume":"30","author":"Siedner","year":"2016","journal-title":"AIDS"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0225","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/380971","article-title":"Amphotericin B treatment for Indian visceral leishmaniasis: conventional versus lipid formulations","volume":"38","author":"Sundar","year":"2004","journal-title":"Clin Infect. Dis."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0230","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/jps.21179","article-title":"Amphotericin B formulations and drug targeting","volume":"97","author":"Torrado","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0235","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4155\/tde.12.134","article-title":"The oral delivery of amphotericin B","volume":"4","author":"Torrado","year":"2013","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0240","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jconrel.2012.05.037","article-title":"PLGA nanoparticles and nanosuspensions with amphotericin B: potent in vitro and in vivo alternatives to Fungizone and AmBisome","volume":"161","author":"Van de Ven","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0245","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3109\/03639045.2014.954587","article-title":"Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature","volume":"41","author":"Wasan","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0250","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1086\/514672","article-title":"Randomized: double-blind clinical trial of amphotericin B colloidal dispersion vs. amphotericin B in the empirical treatment of fever and neutropenia","volume":"27","author":"White","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0255","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0260","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/IJN.S17503","article-title":"Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice","volume":"6","author":"Xu","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0265","doi-asserted-by":"crossref","first-page":"035015","DOI":"10.1088\/1758-5090\/8\/3\/035015","article-title":"An in vitro vascular chip using 3D printing-enabled hydrogel casting","volume":"8","author":"Yang","year":"2016","journal-title":"Biofabrication"},{"key":"10.1016\/j.ijpharm.2017.04.013_bib0270","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.2174\/138920111796117292","article-title":"Recent progress on antifungal drug development","volume":"12","author":"Zhai","year":"2011","journal-title":"Curr. Pharm. Biotechnol."}],"container-title":["International Journal of Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517317302946?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0378517317302946?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T16:43:49Z","timestamp":1568997829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0378517317302946"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["S0378517317302946"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpharm.2017.04.013","relation":{},"ISSN":["0378-5173"],"issn-type":[{"value":"0378-5173","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet clinical needs in the treatment of systemic fungal infections: The role of amphotericin B and drug targeting","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpharm.2017.04.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}